Literature DB >> 23540502

Secondary sclerosing cholangitis: pathogenesis, diagnosis, and management.

Mohamad H Imam1, Jayant A Talwalkar, Keith D Lindor.   

Abstract

Secondary sclerosing cholangitis (SSC) is an aggressive and rare disease with intricate pathogenesis and multiple causes. Understanding the specific cause underlying each case of SSC is crucial in the clinical management of the disease. Radiologic imaging can help diagnose SSC and hence institute management in a timely manner. Management may encompass simple interventions, such as supportive therapy, antibiotics, and monitoring, or more serious measures, such as surgery, endoscopic intervention, or liver transplantation. Patients with AIDS cholangiopathy have limited therapeutic options and worsened survival. The disease should always be highly suspected in patients with primary sclerosing cholangitis with questionable diagnosis. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23540502     DOI: 10.1016/j.cld.2012.11.004

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  9 in total

1.  Docetaxel Induced Sclerosing Cholangitis.

Authors:  Jennifer L Horsley-Silva; Elizabeth N Dow; Christine O Menias; Maxwell L Smith; Estrella M Carballido; Keith D Lindor; Hugo E Vargas
Journal:  Dig Dis Sci       Date:  2015-12       Impact factor: 3.199

Review 2.  Secondary Sclerosing Cholangitis: a Review of Recent Literature.

Authors:  John Brooling; Rolando Leal
Journal:  Curr Gastroenterol Rep       Date:  2017-09

Review 3.  Primary sclerosing cholangitis: diagnosis and treatment.

Authors:  Holger Lutz; Christian Trautwein; Jens W Tischendorf
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

Review 4.  Secondary sclerosing cholangitis in critically ill patients: current perspectives.

Authors:  Hafsteinn O Gudnason; Einar S Björnsson
Journal:  Clin Exp Gastroenterol       Date:  2017-06-23

5.  Liver transplantation following hepatic artery avulsion in a trauma patient.

Authors:  Lara Fernández Cepedal; Mikel Gastaca Mateo; Mikel Prieto Calvo; Andrés Valdivieso López; Laura Fernández Gómez Cruzado; Christian Perez González; Arkaitz Perfecto Valero; Alberto Colina Alonso
Journal:  J Surg Case Rep       Date:  2019-04-06

6.  Secondary sclerosing cholangitis in critically ill patients has a poor outcome but lower tumour incidence than primary sclerosing cholangitis.

Authors:  Martha M Kirstein; Thorsten Book; Michael P Manns; Thomas von Hahn; Torsten Voigtländer
Journal:  United European Gastroenterol J       Date:  2020-05-04       Impact factor: 4.623

7.  Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature.

Authors:  Caroline Klindt; Björn-Erik Jensen; Timo Brandenburger; Torsten Feldt; Alexander Killer; Lars Schimmöller; Gerald Antoch; Tina Senff; Sandra Hauka; Jörg Timm; Bahne Hendrik Bahners; Maximilian Seidl; Irene Esposito; Tom Luedde; Johannes G Bode; Verena Keitel
Journal:  Clin Case Rep       Date:  2021-05-24

8.  Long-Term Outcomes After Drug-Induced Liver Injury.

Authors:  Paul H Hayashi; Einar S Bjornsson
Journal:  Curr Hepatol Rep       Date:  2018-07-02

9.  Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.

Authors:  Zhuo Zhang; Ling Xu; Naishan Qin; Jixin Zhang; Qian Xiang; Qian Liu; Yuanjia Cheng; Yuge Bai; Qianxin Liu; Yinhua Liu; Xuening Duan; Yimin Cui
Journal:  Thorac Cancer       Date:  2021-05-06       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.